Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet.
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Theoretical concentration curve at a half-life of 144 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
These cofactors relate to the peptide class, not to a specific use. No recommendation, no dosing.
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy